Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Cell Mol Neurobiol ; 43(6): 2895-2907, 2023 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-36862242

RESUMO

Isolated sulfite oxidase (ISOD) and molybdenum cofactor (MoCD) deficiencies are genetic diseases biochemically characterized by the toxic accumulation of sulfite in the tissues of patients, including the brain. Neurological dysfunction and brain abnormalities are commonly observed soon after birth, and some patients also have neuropathological alterations in the prenatal period (in utero). Thus, we investigated the effects of sulfite on redox and mitochondrial homeostasis, as well as signaling proteins in the cerebral cortex of rat pups. One-day-old Wistar rats received an intracerebroventricular administration of sulfite (0.5 µmol/g) or vehicle and were euthanized 30 min after injection. Sulfite administration decreased glutathione levels and glutathione S-transferase activity, and increased heme oxygenase-1 content in vivo in the cerebral cortex. Sulfite also reduced the activities of succinate dehydrogenase, creatine kinase, and respiratory chain complexes II and II-III. Furthermore, sulfite increased the cortical content of ERK1/2 and p38. These findings suggest that redox imbalance and bioenergetic impairment induced by sulfite in the brain are pathomechanisms that may contribute to the neuropathology of newborns with ISOD and MoCD. Sulfite disturbs antioxidant defenses, bioenergetics, and signaling pathways in the cerebral cortex of neonatal rats. CII: complex II; CII-III: complex II-III; CK: creatine kinase; GST: glutathione S-transferase; HO-1: heme oxygenase-1; SDH: succinate dehydrogenase; SO32-: sulfite.


Assuntos
Córtex Cerebral , Metabolismo Energético , Cofatores de Molibdênio , Sulfito Oxidase , Sulfitos , Animais , Ratos , Animais Recém-Nascidos , Oxirredução , Sulfitos/efeitos adversos , Sulfito Oxidase/metabolismo , Cofatores de Molibdênio/metabolismo , Ratos Wistar , Homeostase , Mitocôndrias/metabolismo , Córtex Cerebral/efeitos dos fármacos , Córtex Cerebral/metabolismo , Antioxidantes/metabolismo
2.
Arch. argent. pediatr ; 114(3): e195-e198, jun. 2016. ilus
Artigo em Inglês, Espanhol | LILACS, BINACIS | ID: biblio-838226

RESUMO

La anafilaxia es una reacción de hipersensibilidad sistemica y grave, de inicio rápido y potencialmente mortal. En los recién nacidos prematuros, el sistema inmunitario aún no ha madurado y, por lo tanto, tienen menos probabilidades de presentar anafilaxia. La administración de amikacina, que contenía metabisulfito de sodio, a un prematuro de 3 días de vida le indujo anafilaxia casi mortal. Debido a que se sospechaba un caso de anafilaxia, se inició la administración de amikacina en el bebé. Una vez comenzado el tratamiento, se observó una mejoría clínica. Al tercer día de tratamiento con amikacina, el recién nacido tuvo, repentinamente, taquipnea, taquicardia, angioedema y cianosis. Se le diagnosticó anafilaxia y se inició el tratamiento. Una hora después de la mejoría clínica, se produjo una reacción tardía. Inmediatamente, se intubó al recién nacido. La anafilaxia es una emergencia médica; por lo tanto, los médicos deben realizar una evaluación rápida y atenta para detectar esta reacción potencialmente mortal. Incluso después del tratamiento satisfactorio de la anafilaxia, el paciente debe permanecer bajo observación durante 72 horas dada la posibilidad de una reacción bifásica.


Anaphylaxis is a serious systemic hypersensitivity reaction that is rapid in onset and can cause death. Premature newborns, whose immunological system is immature, are less likely to develop anaphylaxis. Administration of amikacin, containing sodium metabisulfite, to a 3-day-old premature newborn, induced a near fatal anaphylaxis. After suspicion of sepsis, the baby was started on amikacin. Clinical improvement was observed after initiation of treatment. On the third day of treatment with amikacin, the newborn suddenly developed tachypnea, tachycardia, angioedema and cyanosis. Anaphylaxis was diagnosed and treated. Latent reaction occurred after one hour of clinical improvement. The baby was intubated immediately. Anaphylaxis is a medical emergency; therefore the clinicians should have a rapid and careful assessment about this potentially fatal reaction. Even after successful treatment of anaphylaxis, the patient should be under observation for 72 hours because of the possibility of a biphasic reaction.


Assuntos
Humanos , Masculino , Recém-Nascido , Sulfitos/efeitos adversos , Amicacina/efeitos adversos , Anafilaxia/etiologia , Antibacterianos/efeitos adversos , Recém-Nascido Prematuro
3.
Arch Argent Pediatr ; 114(3): e195-8, 2016 Jun 01.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-27164357

RESUMO

Anaphylaxis is a serious systemic hypersensitivity reaction that is rapid in onset and can cause death. Premature newborns, whose immunological system is immature, are less likely to develop anaphylaxis. Administration of amikacin, containing sodium metabisulfite, to a 3-day-old premature newborn, induced a near fatal anaphylaxis. After suspicion of sepsis, the baby was started on amikacin. Clinical improvement was observed after initiation of treatment. On the third day of treatment with amikacin, the newborn suddenly developed tachypnea, tachycardia, angioedema and cyanosis. Anaphylaxis was diagnosed and treated. Latent reaction occurred after one hour of clinical improvement. The baby was intubated immediately. Anaphylaxis is a medical emergency; therefore the clinicians should have a rapid and careful assessment about this potentially fatal reaction. Even after successful treatment of anaphylaxis, the patient should be under observation for 72 hours because of the possibility of a biphasic reaction.


La anafilaxia es una reacción de hipersensibilidad sistemica y grave, de inicio rápido y potencialmente mortal. En los recién nacidos prematuros, el sistema inmunitario aún no ha madurado y, por lo tanto, tienen menos probabilidades de presentar anafilaxia. La administración de amikacina, que contenía metabisulfito de sodio, a un prematuro de 3 días de vida le indujo anafilaxia casi mortal. Debido a que se sospechaba un caso de anafilaxia, se inició la administración de amikacina en el bebé. Una vez comenzado el tratamiento, se observó una mejoría clínica. Al tercer día de tratamiento con amikacina, el recién nacido tuvo, repentinamente, taquipnea, taquicardia, angioedema y cianosis. Se le diagnosticó anafilaxia y se inició el tratamiento. Una hora después de la mejoría clínica, se produjo una reacción tardía. Inmediatamente, se intubó al recién nacido. La anafilaxia es una emergencia médica; por lo tanto, los médicos deben realizar una evaluación rápida y atenta para detectar esta reacción potencialmente mortal. Incluso después del tratamiento satisfactorio de la anafilaxia, el paciente debe permanecer bajo observación durante 72 horas dada la posibilidad de una reacción bifásica.


Assuntos
Amicacina/efeitos adversos , Anafilaxia/etiologia , Antibacterianos/efeitos adversos , Sulfitos/efeitos adversos , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Masculino
4.
Pediatr. día ; 14(3): 128-31, jul.-ago. 1998.
Artigo em Espanhol | LILACS | ID: lil-233082

RESUMO

Las reacciones adversas a alimentos es un tema de importancia en la práctica médica y su trascendencia en pediatría adquiere mayor relieve día a día. El estilo de vida y los cambios de hábitos alimentarios que ha impuesto la vida moderna conducen al consumo de una cantidad de elementos ajenos al nutriente natural cuyas consecuencias recién se comienzan a identificar. La mayor parte de esta problemática está rodeada de profundas controversias basadas en la falta de estudios adecuados en muchos casos, pero en muchos otros, en una falta de preocupación por el tema


Assuntos
Doenças Transmitidas por Alimentos , Aditivos Alimentares/efeitos adversos , Corantes de Alimentos/efeitos adversos , Glutamato de Sódio/efeitos adversos , Sulfitos/efeitos adversos
5.
Rev Alerg Mex ; 43(3): 56-61, 1996.
Artigo em Espanhol | MEDLINE | ID: mdl-8963642

RESUMO

Aspirin sensitivity occurs in 10% of all asthmatics patients. In this subset of asthmatics, nasal congestion and bronchospasm occurs between 30-180 minutes after ingestion of aspirin. Following a respiratory reaction to aspirin, all patients can be desensitized to aspirin by repetitively introducing small and then larger doses of aspirin until the asthmatic subject can ingest 650 mg of aspirin without adverse effect. The mechanism of aspirin sensitivity are incompletely understood. And the reasons why ASA desensitization occurs universally are unknown. In this study, known ASA sensitive and control insensitive asthmatics were challenged with ASA. Urine was collected before, during induced bronchospasm, and after ingestion of 650 mg of ASA when the adverse effect (ie., acute desensitization) had subsided. Excretion levels of cyclo-oxygenase and lipoxygenase products in the urine were determined.


Assuntos
Ácido Araquidônico/metabolismo , Aspirina/efeitos adversos , Asma/induzido quimicamente , Dessensibilização Imunológica , Hipersensibilidade a Drogas/etiologia , Leucotrieno E4/urina , Tromboxano B2/urina , Acetaminofen/efeitos adversos , Adulto , Idoso , Aspirina/farmacologia , Aspirina/uso terapêutico , Asma/terapia , Asma/urina , Biotransformação , Espasmo Brônquico/induzido quimicamente , Espasmo Brônquico/urina , Creatinina/sangue , Reações Cruzadas , Inibidores de Ciclo-Oxigenase/farmacologia , Hipersensibilidade a Drogas/terapia , Hipersensibilidade a Drogas/urina , Feminino , Humanos , Hidrocortisona/efeitos adversos , Leucotrienos/biossíntese , Lipoxigenase/metabolismo , Masculino , Pessoa de Meia-Idade , Modelos Imunológicos , Prostaglandina-Endoperóxido Sintases/metabolismo , Sulfitos/efeitos adversos
8.
Alergia (Méx.) ; 36(3): 107-9, mayo-jun. 1989.
Artigo em Espanhol | LILACS | ID: lil-94104

RESUMO

Muchas sustancias químicas se usan para preservar, dar color y sabor a los alimentos, bebidas y medicamentos. Existen numerosos reportes de reacciones adversas incluyendo urticaria, angiodema, asma y anafilaxia, después de la ingestión de aditivos de alimentos como la tartrazina, el glutamato monosódico y el ácido benzoico. Los sulfitos son aditos de alimentos y medicamentos que en forma reciente llamaron la atención médica como causantes de sensibilidad. Se utilizan ampliamente en las industrias de alimentos y bebidas como preservativos y antioxidantes, y en la industria farmaceútica. Este trabajo describe los usos comunes de los sulfitos, así como los mecanismos de sensibilidad, el diagnóstico, prevención y tratamiento de las reacciones adversas inducidas por ellos


Assuntos
Humanos , Masculino , Feminino , História do Século XX , Aditivos Alimentares/efeitos adversos , Hipersensibilidade , Sulfitos , Hipersensibilidade/diagnóstico , Hipersensibilidade/prevenção & controle , Hipersensibilidade/terapia , Sulfitos , Sulfitos/efeitos adversos
9.
Rev Alerg Mex (1987) ; 36(3): 107-9, 1989.
Artigo em Espanhol | MEDLINE | ID: mdl-2672278

RESUMO

Many chemicals are used to preserve, color and flavor foods and drugs. There have been numerous reports of adverse reactions, including urticaria, angioneurotic edema, asthma an anaphylaxis following the ingestion of food additives such as tartrazine, monosodium glutamate and benzoic acid. Recently the food and drug additives reaching medical awareness as a cause of sensitivity are the sulfiting agents. Sulfites are widely used in the food and beverage industry as preservatives and antioxidants. They are also used by the pharmaceutical industry. This work describes the common uses of sulfiting agents, the mechanisms of sulfite sensitivity, the diagnosis, prevention and treatment of adverse reactions to sulfites.


Assuntos
Conservantes de Alimentos/efeitos adversos , Sulfitos/efeitos adversos , Antioxidantes/efeitos adversos , Hipersensibilidade Alimentar/diagnóstico , Hipersensibilidade Alimentar/etiologia , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA